Tag Archives for Merck

Pharma Company to Pay Over $900M from Vioxx Marketing Practices

The DOJ decision has been handed down. Merck Co. will pay $321.6 million in criminal fines and $628.4 million as a civil settlement agreement. It also will plead guilty to a misdemeanor charge stemming from the premature marketing of the … Continue reading

22. November 2011 by Michael Douglas, MD, MBA
Categories: Corporate, Pharma & Devices, Politics & The Law | Tags: , , , , | Comments Off

Lessons from Vioxx News Offers Potential for Tighter Drug Data Surveillance

With the recent story of Vioxx — and its potentially troublesome adverse effects possibly being known to its pharma company before initial launch — hitting the wires yesterday, there is renewed concern of the process by which study results, both … Continue reading

25. November 2009 by Michael Douglas, MD, MBA
Categories: Corporate, Pharma & Devices | Tags: , | Comments Off

Study: Vioxx Risk of Death Known Almost Three Years Before Market Withdrawal

Pharma company Merck withdrew the popular anti-inflammatory agent Vioxx (rofecoxib) from the marketplace in 2004 for increased risk of death due to adverse cardiovascular events, including death. This followed testimony from that company’s CEO before a committee in the Senate … Continue reading

24. November 2009 by Michael Douglas, MD, MBA
Categories: Pharma & Devices, Science & Research | Tags: , | Comments Off

Pharma Company Stands Behind Drug in Face of Potential Negative Sales Impact from Latest Study

http://www.youtube.com/watch?v=vI4Fv0rLYRk&feature=player_embedded”

How can a drug’s study results involving just over 200 or so participants shake up healthcare policy? If the name of that drug is Zetia, there’s already enough political baggage that is making that happen. Statements like the following from … Continue reading

17. November 2009 by Michael Douglas, MD, MBA
Categories: Pharma & Devices | Tags: , | Comments Off

Pharma Company Creates Fake Peer-Reviewed Journal

Pharma giant Merck created a completely bogus medical journal creatively entitled the Australian Journal of Bone and Joint Medicine to publish data favorable to its products. This really comes as no surprise at the hands of a pharma company whose … Continue reading

03. May 2009 by Michael Douglas, MD, MBA
Categories: Knowledge & Medicine, Science & Research | Tags: | 1 comment

Performance-Based Drug Contracts: A Good Fit for Pharma and Health Insurers?

It’s a marriage of self interests among Pharma and Big Insurance. Merck and Cigna just announced a partnership which involves the applications of drug discounts from the pharma company as a benefit to the healthcare payer if patients “perform” well … Continue reading

24. April 2009 by Michael Douglas, MD, MBA
Categories: Pharma & Devices | Tags: , | Comments Off

Tuesday Newswire: An FDA Smorgasbord

Apparently not much is being done to to force fiduciary relationships between pharma companies and the physicians who study and test devices on their patients as subjects. A report [PDF] commissioned by the HHS Dept. confirms the findings. FT Editorial: … Continue reading

13. January 2009 by Michael Douglas, MD, MBA
Categories: Pharma & Devices | Tags: , , , , | Comments Off